Preview

Трансляционная медицина

Расширенный поиск

ВЗАИМОСВЯЗЬ МЕЖДУ ТИРЕОИДНОЙ ПАТОЛОГИЕЙ И САХАРНЫМ ДИАБЕТОМ 2-ГО ТИПА

https://doi.org/10.18705/2311-4495-2017-4-2-29-39

Полный текст:

Аннотация

У пациентов с сахарным диабетом 2-го типа (СД2) чаще, чем в остальной популяции, встречаются дисфункции тиреоидной системы. В основе этого лежит функциональная взаимосвязь между тиреотоксикозом и гипотиреозом, с одной стороны, и развитием инсулиновой резистентности и СД2, с другой, что доказывается как данными клинических исследований, так и результатами, полученными с использованием экспериментальных моделей этих заболеваний. Нарушение баланса тиреоидных гормонов при гипотиреозе и тиреотоксикозе может быть отправной точкой для развития инсулиновой резистентности и в дальнейшем, при неблагоприятном сценарии, вызывать СД2. С другой стороны, метаболические и гормональные нарушения, возникающие в условиях СД2, могут приводить к заболеваниям тиреоидной системы. Лечение тиреоидными гормонами пациентов с сочетанными СД2 и гипотиреозом приводит к восстановлению инсулиновой чувствительности и энергетического гомеостаза. Однако избыточное поступление тиреоидных гормонов ведет к снижению инсулиновой чувствительности, нарушениям углеводного и липидного обмена, что должно учитываться при разработке стратегии лечения СД2 и дисфункций щитовидной железы. Настоящий обзор посвящен современному состоянию проблемы взаимосвязи между СД2 с характерными для него инсулиновой резистентностью, гипергликемией и дислипидемией, и различными формами тиреоидной патологии.

Об авторе

Александр Олегович Шпаков
Федеральное государственное бюджетное учреждение науки «Институт эволюционной физиологии и биохимии им. И. М. Сеченова» Российской академии наук, Санкт-Петербург
Россия

д. б. н., заведующий лабораторией молекулярной эндокринологии и нейрохимии

пр. Тореза, д. 44, Санкт-Петербург, 194223



Список литературы

1. Roos A, Bakker SJ, Links TP et al. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J. Clin. Endocrinol. Metab. 2007; 92:491–496.

2. Garduño-Garcia Jde J, Alvirde-Garcia U, López-Carrasco G et al. TSH and free thyroxine concentrations are associated with differing metabolic markers in euthyroid subjects. Eur. J. Endocrinol. 2010; 163:273–278.

3. Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA. 2005; 294 :71–80.

4. Collet TH, Gussekloo J, Bauer DC et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch. Intern. Med. 2012; 172:799–809.

5. Perros P, McCrimmon RJ, Shaw G, Frier BM. Frequency of thyroid dysfunction in diabetic patients: value of annual screening. Diabet. Med. 1995; 12:622–627.

6. Akbar DH, Ahmed MM, Al-Mughales J. Thyroid dysfunction and thyroid autoimmunity in Saudi type 2 diabetics. Acta Diabetologica. 2006; 43: 14–18.

7. Duntas LH, Orgiazzi J, Brabant G. The interface between thyroid and diabetes mellitus. Clin. Endocrinol. 2011; 75:1–9.

8. Al-Geffari M, Ahmad NA, Al-Sharqawi AH et al. Risk factors for thyroid dysfunction among type 2 diabetic patients in a highly diabetes mellitus prevalent society. Int. J. Endocrinol. 2013; 2013:417920.

9. Demitrost L, Ranabir S. Thyroid dysfunction in type 2 diabetes mellitus: A retrospective study. Indian J. Endocrinol. Metab. 2012; 16:S334–S335.

10. Díez JJ, Iglesias P. An analysis of the relative risk for hypothyroidism in patients with Type 2 diabetes. Diabet. Med. 2012 ; 29:1510–1514.

11. Tamez-Pérez HE, Martínez E, Quintanilla-Flores DL et al. The rate of primary hypothyroidism in diabetic patients is greater than in the non-diabetic population. Med. Clin. 2012; 138:475–477.

12. Ashrafuzzaman SM, Taib AN, Rahman R, Latif ZA. Prevalence of diabetes among hypothyroid subjects. Mymensingh. Med. J. 2012; 21:129–132.

13. Palma CC, Pavesi M, Nogueira VG et al. Prevalence of thyroid dysfunction in patients with diabetes mellitus. Diabetol. Metab. Syndr. 2013 ; 5:58.

14. Chen HS, Wu TE, Jap TS et al. Subclinical hypothyroidism is a risk factor for nephropathy and cardiovascular diseases in Type 2 diabetic patients. Diabet. Med. 2007; 24:1336–1344.

15. Dimitriadis GD, Raptis SA. Thyroid hormone excess and glucose intolerance. Exp. Clin. Endocrinol. Amp. Diabetes. 2001; 109:S225–S239.

16. Brenta G. Why can insulin resistance be a natural consequence of thyroid dysfunction? J. Thyroid Res. 2011; 2011:152850.

17. Lambadiari V, Mitrou P, Maratou E et al. Thyroid hormones are positively associated with insulin resistance early in the development of type 2 diabetes. Endocrine. 2011; 39: 28–32.

18. Potenza M, Via MA, Yanagisawa RT. Excess thyroid hormone and carbohydrate metabolism. Endocr. Pract. 2009; 15:254–262.

19. Beylot M. Regulation of in vivo ketogenesis: role of free fatty acids and control by epinephrine, thyroid hormones, insulin and glucagon. Diabetes Metab. 1996; 22:299–304.

20. Feng X, Jiang Y, Meltzer P, Yen PM. Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray. Mol. Endocrinol. 2000; 14:947–955.

21. Klieverik LP, Janssen SF, Van Riel A et al. Thyroid hormone modulates glucose production via a sympathetic pathway from the hypothalamic paraventricular nucleus to the liver. Proc. Natl. Acad. Sci. USA. 2009; 106:5966–5971.

22. Mokuno T, Uchimura K, Hayashi R et al. Glucose transporter 2 concentrations in hyper- and hypothyroid rat livers. J. Endocrinol. 1999; 160:285–289.

23. Dimitriadis GD, Leighton B, Vlachonikolis IG et al. Effects of hyperthyroidism on the sensitivity of glycolysis and glycogen synthesis to insulin in the soleus muscle of the rat. Biochem. J. 1988; 253:87–92.

24. Leighton B, Dimitriadis GD, Oarry-Billings M et al. Thyroid hormone analogue SKF L-94901: effects on amino acid and carbohydrate metabolism in rat skeletal muscle in vitro. Biochem. Pharmacol. 1990; 40:1161–1164.

25. Dimitriadis G, Mitrou P, Lambadiari V et al. Insulin-stimulated rates of glucose uptake in muscle in hyperthyroidism: the importance of blood flow. J. Clin. Endocrinol. Metab. 2008; 93:2413–2415.

26. Mitrou P, Boutati E, Lambadiari V et al. Insulin resistance in hyperthyroidism: the role of IL6 and TNFα. Eur. J. Endocrinol. 2010; 162:121–126.

27. Ximenes HM, Lortz S, Jörns A, Lenzen S. Triiodothyronine (T3)-mediated toxicity and induction of apoptosis in insulin-producing INS-1 cells. Life Sci.. 2007; 80:2045–2050.

28. Randin JP, Tappy L, Scazziga B. Insulin sensitivity and exogenous insulin clearance in Graves’ disease. Measurement by the glucose clamp technique and continuous indirect calorimetry. Diabetes. 1986; 35:178–181.

29. Dimitriadis G, Hatziagelaki E, Mitrou P et al. Effect of hyperthyroidism on clearance and secretion of glucagon in man. Exp. Clin. Endocrinol. Diabetes. 2011; 119:214–217.

30. Yavuz DG, Yüksel M, Deyneli O et al. Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goitre patients. Clin. Endocrinol. 2004; 61:515–521.

31. Maratou E, Hadjidakis DJ, Peppa M et al. Studies of insulin resistance in patients with clinical and subclinical hyperthyroidism. Eur. J. Endocrinol. 2010; 163:625–630.

32. Rezzonico J, Niepomniszcze H, Rezzonico M et al. The association of insulin resistance with subclinical thyrotoxicosis. Thyroid. 2011; 21:945–949.

33. Brenta G, Celi FS, Pisarev M et al. Acute thyroid hormone withdrawal in athyreotic patients results in a state of insulin resistance. Thyroid. 2009; 19:665–669.

34. Wang C. The relationship between type 2 diabetes mellitus and related thyroid diseases. J. Diabetes Res. 2013; 2013:390534.

35. Czech MP, Malbon CC, Kerman K et al. Effect of thyroid status on insulin action in rat adipocytes and skeletal muscle. J. Clin. Invest. 1980; 66:574–582.

36. Dimitriadis G, Parry-Billings M, Bevan S et al. The effects of insulin on transport and metabolism of glucose in skeletal muscle from hypothyroid rats. Eur. J. Clin. Invest. 1997; 27:475–483.

37. Peppa M, Koliaki C, Nikolopoulos P, Raptis SA. Skeletal muscle insulin resistance in endocrine disease. J. Biomed. Biotechnol. 2010; 2010:527850.

38. Cettour-Rose P, Theander-Carrillo C, Asensio C et al. Hypothyroidism in rats decreases peripheral glucose utilization, a defect partially corrected by central leptin infusion. Diabetologia. 2005; 48:624–633.

39. Shpakov AO, Derkach KV. Brain hormonal systems and type 2 diabetes mellitus. Spb: Izdatel’stvo Politekhnicheskogo universiteta, 2015. p. 252. In Russian. [Шпаков АО, Деркач КВ. Гормональные системы мозга и сахарный диабет 2-го типа. СПб.: Издательство Политехнического университета, 2015. с. 252].

40. Chen Y, Wu X, Wu R et al. Changes in profile of lipids and adipokines in patients with newly diagnosed hypothyroidism and hyperthyroidism. Sci. Rep. 2016; 6:26174.

41. Derkach KV, Shpakova EA, Zharova OA, Shpakov AO. The metabolic changes in rats immunized with BSA conjugate of peptide derived from the N-terminal region of type 4 melanocortin receptor. Dokl. Biochem. Biophys. 2014; 458:163–166.

42. Shpakov AO. The role of disturbances in hormonal signaling systems in etiology and pathogenesis of diabetes mellitus. J. Evol. Biochem. Physiol. 2014; 50:552–556.

43. Shpakov AO, Derkach KV, Zharova OA, Shpakova EA. The functional activity of the adenylyl cyclase system in the brain of rats with metabolic syndrome that induced by immunization with the 11–25 peptide of the melanocortin receptor of the fourth type. Neurochem. J. 2015; 9:29–38.

44. Ashwini S, Bobby Z, Joseph M. Mild hypothyroidism improves glucose tolerance in experimental type 2 diabetes. Chem. Biol. Interact. 2015; 235:47–55.

45. Ahmed OM, Gabar MA, Ali TM. Impacts of the coexistence of diabetes and hypothyroidism on body weight gain, leptin and various metabolic aspects in albino rats. J. Diabetes Complications. 2012; 26:491–500.

46. Rochon C, Tauveron I, Dejax C et al. Response of glucose disposal to hyperinsulinaemia in human hypothyroidism and hyperthyroidism. Clin. Sci. (Lond.). 2003; 104:7–15.

47. Stanicka S, Vondra K, Pelikanova T et al. Insulin sensitivity and counter-regulatory hormones in hypothyroidism and during thyroid hormone replacement therapy. Clin. Chem. Lab. Med. 2005; 43:715–720.

48. Handisurya A, Pacini G, Tura A et al. Effects of thyroxine replacement therapy on glucose metabolism in subjects with subclinical and overt hypothyroidism. Clin. Endocrinol. 2008; 69:963–969.

49. Dimitriadis G, Mitrou P, Lambadiari V et al. Insulin action in adipose tissue and muscle in hypothyroidism. J. Clin. Endocrinol. Metab. 2006; 91:4930–4937.

50. Brenta G, Danzi S, Klein I. Potential therapeutic applications of thyroid hormone analogs. Nat. Clin. Pract. Endocrinol. Metab. 2007; 3:632–640.

51. Harris PE, Walker M, Clark F et al. Forearm muscle metabolism in primary hypothyroidism. Eur. J. Clin. Invest. 1993; 23:585–588.

52. Owecki M, Nikisch E, Sowiński J. Hypothyroidism has no impact on insulin sensitivity assessed with HOMA-IR in totally thyroidectomized patients. Acta Clinica Belgica. 2006; 61:69–73.

53. Tuzcu A, Bahceci M, Gokalp D et al. Subclinical hypothyroidism may be associated with elevated high sensitive C-reactive protein (low grade inflammation) and fasting hyperinsulinemia. Endocr. J. 2005; 52:89–94.

54. Vyakaranam S, Vanaparthy S, Nori S et al. Study of insulin resistance in subclinical hypothyroidism. Int. J. Health Sci. Res. 2014; 4:147–153.

55. El-Eshmawy MM, Abd El-Hafez HA, El Shabrawy WO et al. Response: subclinical hypothyroidism is independently associated with microalbuminuria in a cohort of prediabetic egyptian adults. Diabetes Metab. J. 2014; 38:85–86.

56. Kim SR, Tull ES, Talbott EO et al. A hypothesis of synergism: the interrelationship of T3 and insulin to disturbances in metabolic homeostasis. Med. Hypotheses. 2002; 59:660–666.

57. Skarulis M, Celi F, Mueller E et al. Thyroid hormone induced brown adipose tissue and amelioration of diabetes in a patient with extreme insulin resistance. J. Clin. Endocrinol. Metab. 2010; 95:256–262.

58. Pearce S, Brabant G, Duntas L et al. 2013 ETA guideline: management of subclinical hypothyroidism. Eur. Thyroid J. 2013; 2:215–228.

59. Javed Z, Sathyapalan T. Levothyroxine treatment of mild subclinical hypothyroidism: a review of potential risks and benefits. Ther. Adv. Endocrinol. Metab. 2016; 7:12–23.

60. Cho JH, Kim HJ, Lee JH et al. Poor glycemic control is associated with the risk of subclinical hypothyroidism in patients with type 2 diabetes mellitus. Korean J. Intern. Med. 2016; 31:703–711.


Для цитирования:


Шпаков А.О. ВЗАИМОСВЯЗЬ МЕЖДУ ТИРЕОИДНОЙ ПАТОЛОГИЕЙ И САХАРНЫМ ДИАБЕТОМ 2-ГО ТИПА. Трансляционная медицина. 2017;4(2):29-39. https://doi.org/10.18705/2311-4495-2017-4-2-29-39

For citation:


Shpakov A.O. RELATIONSHIP BETWEEN THYROID DISEASES AND TYPE 2 DIABETES MELLITUS. Translational Medicine. 2017;4(2):29-39. (In Russ.) https://doi.org/10.18705/2311-4495-2017-4-2-29-39

Просмотров: 261


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2311-4495 (Print)
ISSN 2410-5155 (Online)